365 related articles for article (PubMed ID: 22409867)
1. Targeted therapies for advanced non-small cell lung cancer.
Starakis I; Nikolakopoulos A; Mazokopakis EE
Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
[TBL] [Abstract][Full Text] [Related]
2. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
3. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Pakkala S; Ramalingam SS
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
[TBL] [Abstract][Full Text] [Related]
7. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Bronte G; Rolfo C; Giovannetti E; Cicero G; Pauwels P; Passiglia F; Castiglia M; Rizzo S; Vullo FL; Fiorentino E; Van Meerbeeck J; Russo A
Crit Rev Oncol Hematol; 2014 Feb; 89(2):300-13. PubMed ID: 24041630
[TBL] [Abstract][Full Text] [Related]
8. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
[TBL] [Abstract][Full Text] [Related]
9. Investigational agents in the management of non-small cell lung cancer.
Pennell NA; Mekhail T
Curr Oncol Rep; 2009 Jul; 11(4):275-84. PubMed ID: 19508832
[TBL] [Abstract][Full Text] [Related]
10. [New biological treatments for lung cancer].
Zalcman G; Richard N; Bergot E
Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
[TBL] [Abstract][Full Text] [Related]
11. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
13. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
14. Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
Rossi A; Maione P; Colantuoni G; Ferrara C; Rossi E; Guerriero C; Nicolella D; Falanga M; Palazzolo G; Gridelli C
Curr Drug Discov Technol; 2009 Jun; 6(2):91-102. PubMed ID: 19519336
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q; Baijal S; Taniere P; O'Sullivan B; Evans M; Middleton G
Pathol Oncol Res; 2018 Oct; 24(4):723-731. PubMed ID: 29270776
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
17. New insights in drug development for the non-small cell lung cancer therapy.
Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
[TBL] [Abstract][Full Text] [Related]
18. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
19. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
20. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
Takeda M; Nakagawa K
Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]